Journal of Neurology

, Volume 259, Issue 11, pp 2419–2423 | Cite as

Smoking-induced transient motor deterioration in a levodopa-treated patient with Parkinson’s disease

  • Helen LingEmail author
  • Igor Petrovic
  • Brian L. Day
  • Andrew J. Lees
Original Communication


We report a 53-year-old patient with Parkinson’s disease who complained of transient worsening of motor symptoms after smoking a tobacco cigarette. She had been a chronic smoker of one packet of cigarettes a day for over 20 years. We objectively assessed her motor performance including repetitive finger tapping (RFT) speed using 3D kinematic recordings, timed finger tapping test (TFT) and Unified Parkinson’s Disease Rating Scale (UPDRS) III before and after the administration of nicotine, and with and without levodopa. Nicotine was delivered by either smoking a cigarette or by intranasal nicotine spray. Without levodopa, acute deterioration in RFT speed was observed 10 min after both routes of nicotine administration. With levodopa, there was acute deterioration in RFT speed after smoking cigarette, followed by a delayed rebound improvement. However, the administration of nicotine spray led to immediate and sustained motor improvement without initial deterioration. UPDRS III and TFT showed similar trends of acute motor deterioration after either smoking or use of the spray without intake of levodopa. Transient motor worsening after smoking tobacco has been previously reported in only one patient with Parkinson’s disease. The objective findings of acute motor deterioration following both cigarette smoking and nicotine spray administration suggest that nicotine might be the cause of the negative motor effects in this patient. Similar changes were not observed after the administration of placebo intranasal spray. At low dose or beginning of dose, nicotine induces sub-threshold stimulation of dopamine release, which selectively activates the pre-synaptic D2 autoreceptors, leading to transient motor worsening. The potential mechanisms of the additive effect of levodopa and nicotine and paradoxical motor improvement after administration of high-dose nicotine via intranasal nicotine spray are also discussed.


Nicotine Parkinson’s disease Parkinsonism Levodopa Cigarette Smoking 



We are grateful to our patient who agreed to participate in this study.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Supplementary material

Supplementary video In the absence of levodopa therapy, the patient was hypomimic at baseline. Bradykinesia was observed during hand opening and closing and repetitive finger tapping. Pull test was negative. There was worsening of bradykinesia on finger tapping 10 min after either smoking one cigarette or intranasal nicotine spray administration. There was retropulsion on pull test 10 min after nicotine spray. (WMV 4607 kb)


  1. 1.
    Baron JA (1986) Cigarette smoking and Parkinson’s disease. Neurology 36:1490–1496PubMedCrossRefGoogle Scholar
  2. 2.
    Benoit-Marand M, Borrelli E, Gonon F (2001) Inhibition of dopamine release via presynaptic D2 receptors: time course and functional characteristics in vivo. J Neurosci 21:9134–9141PubMedGoogle Scholar
  3. 3.
    Clemens P, Baron JA, Coffey D, Reeves A (1995) The short-term effect of nicotine chewing gum in patients with Parkinson’s disease. Psychopharmacology 117:253–256PubMedCrossRefGoogle Scholar
  4. 4.
    Colosimo C, Inghilleri M (2012) A further case of nicotine sensitivity in multiple system atrophy. Clin Neuropharmacol 35:51–52PubMedCrossRefGoogle Scholar
  5. 5.
    Dogu O, Johnson J, Hernandez D, Hanson M, Hardy J, Apaydin H, Ozekmekci S, Sevim S, Gwinn-Hardy K, Singleton A (2004) A consanguineous Turkish family with early onset Parkinson’s disease and an exon 4 parkin deletion. Mov Disord 19:812–816PubMedCrossRefGoogle Scholar
  6. 6.
    Ebersbach G, Stock M, Muller J, Wenning G, Wissel J, Poewe W (1999) Worsening of motor performance in patients with Parkinson’s disease following transdermal nicotine administration. Mov Disord 14:1011–1013PubMedCrossRefGoogle Scholar
  7. 7.
    Fagerstrom KO, Pomerleau O, Giordani B, Stelson F (1994) Nicotine may relieve symptoms of Parkinson’s disease. Psychopharmacology 116:117–119PubMedCrossRefGoogle Scholar
  8. 8.
    Graham JG, Oppenheimer DR (1969) Orthostatic hypotension and nicotine sensitivity in a case of multiple system atrophy. J Neurol Neurosurg Psychiatry 32:28–34PubMedCrossRefGoogle Scholar
  9. 9.
    Hanagasi HA, Lees A, Johnson JO, Singleton A, Emre M (2007) Smoking-responsive juvenile-onset Parkinsonism. Mov Disord 22:115–119PubMedCrossRefGoogle Scholar
  10. 10.
    Ishikawa A, Miyatake T (1993) Effects of smoking in patients with early onset Parkinson’s disease. J Neurol Sci 117:28–32PubMedCrossRefGoogle Scholar
  11. 11.
    Kelton MC, Kahn HJ, Conrath CL, Newhouse PA (2000) The effects of nicotine on Parkinson’s disease. Brain Cogn 43:274–282PubMedGoogle Scholar
  12. 12.
    Lemay S, Chouinard S, Blanchet P, Masson H, Soland V, Beuter A, Bedard MA (2004) Lack of efficacy of a nicotine transdermal treatment on motor and cognitive deficits in Parkinson’s disease. Prog Neuropsychopharmacol Biol Psychiatry 28:31–39PubMedCrossRefGoogle Scholar
  13. 13.
    Marshall J, Schnieden H (1966) Effect of adrenaline, noradrenaline, atropine, and nicotine on some types of human tremor. J Neurol Neurosurg Psychiatry 29:214–218PubMedCrossRefGoogle Scholar
  14. 14.
    Merello M, Lees AJ (1992) Beginning-of-dose motor deterioration following the acute administration of levodopa and apomorphine in Parkinson’s disease. J Neurol Neurosurg Psychiatry 55:1024–1026PubMedCrossRefGoogle Scholar
  15. 15.
    Nishimura H, Tachibana H, Okuda B, Sugita M (1997) Transient worsening of Parkinson’s disease after cigarette smoking. Intern Med 36:651–653PubMedCrossRefGoogle Scholar
  16. 16.
    Paisan-Ruiz C, Guevara R, Federoff M, Hanagasi H, Sina F, Elahi E, Schneider SA, Schwingenschuh P, Bajaj N, Emre M, Singleton AB, Hardy J, Bhatia KP, Brandner S, Lees AJ, Houlden H (2010) Early onset l-dopa-responsive parkinsonism with pyramidal signs due to ATP13A2, PLA2G6, FBXO7 and spatacsin mutations. Mov Disord 25:1791–1800PubMedCrossRefGoogle Scholar
  17. 17.
    Quik M (2004) Smoking, nicotine and Parkinson’s disease. Trends Neurosci 27:561–568PubMedCrossRefGoogle Scholar
  18. 18.
    Schneider JS, Van Velson M, Menzaghi F, Lloyd GK (1998) Effects of the nicotinic acetylcholine receptor agonist SIB-1508Y on object retrieval performance in MPTP-treated monkeys: comparison with levodopa treatment. Ann Neurol 43:311–317PubMedCrossRefGoogle Scholar
  19. 19.
    Vieregge A, Sieberer M, Jacobs H, Hagenah JM, Vieregge P (2001) Transdermal nicotine in Parkinson’s disease: a randomized, double-blind, placebo-controlled study. Neurology 57:1032–1035PubMedCrossRefGoogle Scholar
  20. 20.
    Villafane G, Cesaro P, Rialland A, Baloul S, Azimi S, Bourdet C, Le Houezec J, Macquin-Mavier I, Maison P (2007) Chronic high dose transdermal nicotine in Parkinson’s disease: an open trial. Eur J Neurol 14:1313–1316PubMedCrossRefGoogle Scholar
  21. 21.
    Wonnacott S, Barik J, Dickinson J, Jones IW (2006) Nicotinic receptors modulate transmitter cross talk in the CNS: nicotinic modulation of transmitters. J Mol Neurosci 30:137–140PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Helen Ling
    • 1
    • 2
    • 3
    Email author
  • Igor Petrovic
    • 1
    • 4
  • Brian L. Day
    • 5
  • Andrew J. Lees
    • 1
    • 2
    • 3
  1. 1.Reta Lila Weston Institute of Neurological Studies, Institute of NeurologyUniversity College LondonLondonUK
  2. 2.Sara Koe PSP Research Centre, Institute of NeurologyUniversity College LondonLondonUK
  3. 3.Queen Square Brain Bank for Neurological Disorders, Institute of NeurologyUniversity College LondonLondonUK
  4. 4.Institute of Neurology CCSBelgradeSerbia
  5. 5.Sobell Department of Motor Neuroscience and Movement Disorders, Institute of NeurologyUniversity College LondonLondonUK

Personalised recommendations